Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Islet Transplantation in Type 1 Diabetic Kidney Allograft

Phase 2

Recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Biological: Allogenic islet cells (human, U. Chicago)
Procedure: Intraportal infusion of islet cells

First Posted Date: 2010-11-16

Last Posted Date: 2024-11-26

Lead Sponsor: University of Chicago

Target Recruit Count: 10

Registration Number: NCT01241864

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors

Not Applicable

Completed

Conditions: Pancreatic Cysts

Interventions: Device: Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system

First Posted Date: 2010-11-07

Last Posted Date: 2016-06-08

Lead Sponsor: University of Chicago

Target Recruit Count: 66

Registration Number: NCT01236300

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Topical Allstate and Nasal Allergen Challenge

Phase 3

Withdrawn

Conditions: Allergic Rhinitis

Interventions: Device: Allstate Nasal Spray
Device: Placebo Nasal Spray

First Posted Date: 2010-11-01

Last Posted Date: 2013-06-03

Lead Sponsor: University of Chicago

Registration Number: NCT01231724

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)

Phase 3

Withdrawn

Conditions: Substance Abuse
Depression
Anxiety
Externalizing Symptoms

Interventions: Behavioral: CATCH-IT
Behavioral: AMPE

First Posted Date: 2010-10-27

Last Posted Date: 2012-12-17

Lead Sponsor: University of Chicago

Registration Number: NCT01228890

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Access Community Health Network, Chicago, Illinois, United States
🇺🇸
Northshore University Health Systems, Evanston, Illinois, United States

and more 1 locations

Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer

Phase 1

Completed

Conditions: Melanoma
Tumor
Carcinoma
Cancer
Sarcoma

Interventions: Radiation: Hypofractionated RT

First Posted Date: 2010-10-06

Last Posted Date: 2018-09-12

Lead Sponsor: University of Chicago

Target Recruit Count: 63

Registration Number: NCT01215500

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer

Completed

Conditions: Urothelial Cancer

First Posted Date: 2010-09-21

Last Posted Date: 2018-05-04

Lead Sponsor: University of Chicago

Target Recruit Count: 79

Registration Number: NCT01206426

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Laser Based Focal Ablation of Low Grade Prostate Cancer

Not Applicable

Completed

Conditions: Low Grade Prostate Cancer

Interventions: Procedure: Laser-based thermotherapy

First Posted Date: 2010-09-01

Last Posted Date: 2014-03-27

Lead Sponsor: University of Chicago

Target Recruit Count: 9

Registration Number: NCT01192438

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2010-08-24

Last Posted Date: 2023-11-29

Lead Sponsor: University of Chicago

Target Recruit Count: 35

Registration Number: NCT01187472

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Androderm® 2.5mg
Drug: Androderm® 5.0mg
Drug: Androderm® 7.5mg

First Posted Date: 2010-08-24

Last Posted Date: 2023-11-29

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT01187485

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: ZD1839 (IRESSA)

First Posted Date: 2010-08-19

Last Posted Date: 2023-11-29

Lead Sponsor: University of Chicago

Target Recruit Count: 46

Registration Number: NCT01185158

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy